HOW IT WORKS
The ivWatch Model 400 uses light to continuously monitor a patient’s subcutaneous tissue and measures the changes in the optical properties of the tissue.
ivWatch Model 400 Overview
The ivWatch Model 400 consists of 3 main components:
- The ivWatch Patient Monitor that is mounted to the pole and displays the state of a patient’s IV
- A sterile and disposable receptacle that secures the sensor to the patient’s skin
- A multi-use sensor cable that includes a non-invasive sensor
Once the device is connected to the patient, the ivWatch Model 400 uses light to continuously monitor a patient’s subcutaneous tissue and measures the changes in the optical properties of the tissue. The sensor cable delivers the light signals from the ivWatch patient monitor to the patient’s skin through the sensor head. The sensor head transmits the reflected light from the tissue back to the patient monitor through the sensor cable. The amount of light detected by the sensor depends primarily on the scattering and absorption properties of the monitored tissue. Scattering occurs when a light particle is redirected due to an interaction with some structure, such as fluid, in the tissue. Absorption occurs when the light particle is absorbed by a structure in the tissue, such as hemoglobin in blood.
During an infiltration, fluid accumulates in subcutaneous tissue, causing a significant change in the light scattering. The ivWatch Model 400 recognizes these changes in the reflected light, first providing a YELLOW CHECK IV notification indicating the possibility of an infiltration. If the infusion continues and the signal continues to drop further below the threshold, a RED CHECK IV notification will appear on the monitor, indicating a probable infiltration. The signal processing algorithm used to issue the YELLOW and RED CHECK IV notifications is optimized to maximize sensitivity and specificity for infiltration events, while minimizing the number of false alarms from other events such as patient motion. This algorithm is based on years of clinical and real-world research and data.
“The company believes that their line of devices could be the difference between success and failure when it comes to peripheral IV therapy, with early detection being the crucial component to producing better patient outcomes.”
“The depth of science and technology behind the product is profound, requiring an ample amount of research and prototypes before it was perfected.”
“In the hospital’s pediatric intensive care unit, healthcare workers have observed a significant drop in the severity of infiltrations.”
Drug Delivery Business News
“Potential cost savings related to decrease in complications from infiltration would equate to significant benefits to healthcare system and decreased suffering for patients.”
Juror Mary Kay Smith, PhD, MSN, RN, CHSE
Director of the Learning and Assessment Center at Michigan State University
“We have partnered with ivWatch because they offer the most advanced technology to help minimize patient harm through the early detection of IV infiltration events.”
Group Manager, General Hospital Products Group, General Hospital Company at Terumo Corporation
“…ivWatch is a company that has spent 15 years perfecting a solution to a big problem with intravenous infiltrations.”
Human Eye vs ivWatch
ivWatch allows clinicians to leverage technology to help identify infiltrations as early as possible. Many hospitals have implemented programs such as hourly checks, visual assessments, and other internal programs. Unfortunately, infiltrations and extravasations still occur.
ivWatch becomes the clinician’s partner, continuously monitoring for infiltrations. When the ivWatch system detects an infiltration it alerts the clinician to inspect the IV site or supports their own evaluation that an infiltration has occurred.
The use of technology and clinician assessments together can improve patient safety and help minimize patient harm from infiltration and extravasation events.